PRELUDE THERAPEUTICS INC Shareholders' Equity
PRELUDE THERAPEUTICS INC (PRLD) had Shareholders' Equity of $133.73 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $133.73M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $60.18M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $68.64M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $58.53M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $133.73M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $60.18M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $68.64M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $58.53M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $75.84M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $103.18M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $131.46M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $156.43M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $182.28M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $210.73M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $237.09M 10-K · filed 2026-03-10 |
| 2023-09-30 | $238.26M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $262.06M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $175.30M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $195.44M 10-K · filed 2025-03-10 |
| 2022-09-30 | $217.41M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $240.84M 10-Q · filed 2023-11-01 |
| 2022-03-31 | $261.81M 10-Q · filed 2023-11-01 |
| 2021-12-31 | $285.90M 10-K · filed 2024-02-15 |
| 2021-09-30 | $311.24M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $334.36M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $356.57M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $212.18M 10-K · filed 2023-03-15 |
| 2020-09-30 | $228.31M 10-Q · filed 2021-11-12 |
| 2020-06-30 | -$69.31M 10-Q · filed 2021-11-12 |
| 2020-03-31 | -$58.56M 10-Q · filed 2021-11-12 |
| 2019-12-31 | -$49.41M 10-K · filed 2022-03-17 |
| 2019-09-30 | -$39.70M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$33.26M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$27.85M 10-Q · filed 2020-11-10 |
| 2018-12-31 | -$22.69M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |